Trial Profile
The effect of bezafibrate on cholestatic itch
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Bezafibrate (Primary)
- Indications Cholestasis; Pruritus
- Focus Therapeutic Use
- Acronyms FITCH
- 05 Oct 2020 Primary endpoint, Proportion of patients reaching a 50% or more reduction in itch intensity VAS score after 21 days of treatment has been met as per results published in the Gastroenterology
- 05 Oct 2020 Results published in the Gastroenterology
- 13 Jan 2020 This trial has been completed in Spain, according to European Clinical Trials Database.